Clinical Trials Directory

Trials / Completed

CompletedNCT05443867

Monkeypox ASymptomatic Shedding: Evaluation by Self-Sampling MPX-ASSESS

Status
Completed
Phase
Study type
Observational
Enrollment
27 (actual)
Sponsor
Institute of Tropical Medicine, Belgium · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

Monkeypox (MPX) is a viral zoonosis, caused by the Monkeypox virus (MPXV), a DNA virus that belongs to the Orthopoxvirus genus and is closely related to the variola virus, the causative agent of smallpox. Until recently the spread of MPX was mainly confined to the Central African rainforest and to parts of West Africa. However, in May 2022, several cases of MPX were detected throughout Europe and Northern America, albeit with a different presentation than previously seen. Many questions remain on this new presentation of the disease: what the exact mode of transmission is, how contagious the virus really is and whether asymptomatic carriers exist. With this study the researchers aim to perform a close follow-up study of close contacts of MPX confirmed cases. Participants are recruited among high and very high risk contacts of confirmed monkeypox patients that presented to the ITM for diagnosis (index). Contacts that are asymptomatic (for symptoms compatible with MPXV infection according to national case definitions) at the time of recruitment will be enrolled. Contacts of the index case that are symptomatic at recruitment or become symptomatic during follow-up will be invited for sample collection at different timepoints until 21 days after contact as suspect cases.

Conditions

Timeline

Start date
2022-06-22
Primary completion
2022-08-25
Completion
2022-08-25
First posted
2022-07-05
Last updated
2023-09-29

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT05443867. Inclusion in this directory is not an endorsement.